scispace - formally typeset
A

Aleksey Lomakin

Researcher at Massachusetts Institute of Technology

Publications -  74
Citations -  8913

Aleksey Lomakin is an academic researcher from Massachusetts Institute of Technology. The author has contributed to research in topics: Phase (matter) & Protein structure. The author has an hindex of 41, co-authored 74 publications receiving 8449 citations. Previous affiliations of Aleksey Lomakin include Brigham and Women's Hospital & United States Department of Veterans Affairs.

Papers
More filters
Journal ArticleDOI

Amyloid beta -protein (Abeta) assembly: Abeta 40 and Abeta 42 oligomerize through distinct pathways.

TL;DR: In this article, photo-induced cross-linking of unmodified proteins (PICUP) was combined with size-exclusion chromatography, dynamic light scattering, circular dichroism spectroscopy, and electron microscopy to reveal the early assembly of Aβ40 and Aβ42.
Journal ArticleDOI

Amyloid beta-protein fibrillogenesis. Structure and biological activity of protofibrillar intermediates.

TL;DR: Walsh et al. as discussed by the authors found that amyloid protofibrils are in equilibrium with low molecular weight Abeta (monomeric or dimeric) and have a secondary structure characteristic of Amyloid fibrils.
Journal ArticleDOI

On the nucleation and growth of amyloid beta-protein fibrils: detection of nuclei and quantitation of rate constants

TL;DR: The approach provides a powerful means for the quantitative assay of A beta fibrillogenesis and found that the surfactant n-dodecylhexaoxyethylene glycol monoether (C12E6) slowed nucleation and elongation of fibrils in a concentration-dependent manner.
Journal ArticleDOI

Kinetic theory of fibrillogenesis of amyloid β-protein

TL;DR: It is suggested that the method of QLS in combination with this theory can serve as a powerful tool for understanding the molecular factors that control Aβ plaque formation.
Journal ArticleDOI

Development of a Multimarker Assay for Early Detection of Ovarian Cancer

TL;DR: A panel of CA-125, HE4, CEA, and VCAM-1, after additional validation, could serve as an initial stage in a screening strategy for epithelial ovarian cancer.